Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin in immune thrombocytopenia patients with cardiovascular disease
2020-000968-30Phase 4Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aspirin in cardiac morbidity, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Platelet thromboxane B2 production at 24 hours. Started Mar 2021; status: active.
02
Drugs
aspirin
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2020-000968-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000968-30.